HeimDBV • EPA
add
DBV Technologies SA
Við síðustu lokun
2,92 €
Dagbil
2,68 € - 2,94 €
Árabil
0,51 € - 3,18 €
Markaðsvirði
412,66 m. EUR
Meðalmagn
1,07 m.
V/H-hlutf.
-
A/V-hlutfall
-
Aðalkauphöll
EPA
Viðskiptafréttir
Um
DBV Technologies SA is a publicly owned French biopharmaceutical firm headquartered in Bagneux, France. DBV Technologies is known for developing "Viaskin" technology for administering allergens or antigens to intact skin while avoiding any transfer to the blood. Viaskin Peanut clinical development has received Fast Track designation from the US Food and Drug Administration. Wikipedia
Stofnsett
29. mar. 2002
Vefsvæði
Starfsfólk
109